Clinical study of Unani drug in comparison to conventional drug in the treatment of vitiligo (white patches)
- Conditions
- Health Condition 1: L80- Vitiligo
- Registration Number
- CTRI/2019/04/018669
- Lead Sponsor
- Central Research Institute of Unani Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patients of any sex aged18-40 years
Non-segmental vitiligo with chronicity of 6 months to 2 years
Vitiligo involving more than equal to 2% body surface area (BSA)
Patients with less than 5 new lesions in the last month
Patients with less than 15 lesions in the last 3 months
Patients who have not taken systemic treatment in the last 4 weeks
Patients who have not taken topical treatment in the last 2 weeks
Patients aged less than 18 years or more than 40 years
Segmental vitiligo/ lip-tip or universal vitiligo/ vitiligo with leucotrichia
Non-Segmental vitiligo with chronicity of less than 6 months or more than 2 years
History of photosensitivity/ photo exaggerated dermatoses
Pregnant or Lactating Women
Significant Pulmonary/ Cardiovascular/ Hepato-renal Dysfunction
Known cases of Immunocompromised states (HIV/ AIDS, etc.)/ Malignancies (cutaneous or internal)
Patients not willing to attend treatment schedule regularly
Patients not having a suitable facility for sun exposure
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method